NEW YORK (GenomeWeb News) – Orchid Cellmark plans to shut down its paternity testing operations in East Lansing, Mich., and move them to its facilities in Dayton, Ohio, the company said today.

The DNA testing firm plans to bring all of its US paternity operations "under one roof" in an effort to increase efficiency, Orchid CEO Thomas Bologna said in a statement today. The Dayton facility already houses some paternity testing services, and the company's call center and customer operations are based in Dayton as well, Bologna said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.